NuScale Power Drops to 52-Week Low as UBS Sees 40% More Pain

NEW YORK, September 12, The UBS downgrade that sent NuScale Power (SMR) to a 52-week low Friday is less a macro bet against nuclear than a verdict on a specific event: the cancellation of the Utah Associated Municipal Power Systems Carbon Free Power Project, which stripped the revenue base to near-zero and left the company burning $205mn in free cash flow annually against $11mn in trailing revenue.

The Numbers
UBS Sell rating implies 40% downside from the $8.61 close, a target that, if reached, would mark a new post-SPAC floor. TTM revenue: $11mn, down 99.1% YoY, the direct residue of the UAMPS Carbon Free Power Project cancellation. FCF: -$205mn. Trailing EPS: -$1.86; forward P/E: -13.2x. Next catalyst: a binding contract announcement or DOE licensing update demonstrating commercial demand above the near-zero revenue base.

UAMPS Cancellation Reduced Revenue to a Rounding Error

NuScale Power Corporation (SMR) posted TTM revenue of $11mn, down 99.1% year-over-year. The concentration risk is now visible in retrospect: the Utah Associated Municipal Power Systems Carbon Free Power Project was not a major customer, it was effectively the entire commercial franchise. Its cancellation did not slow NuScale's growth; it erased the revenue base. What remains is a development-stage cash profile wearing a public-markets valuation.

UBS's Sell is an observation that $11mn in trailing revenue cannot support the stock's implied enterprise value at any sensible multiple. The wire services are calling this a downgrade. The more precise framing: UBS is forcing into the open a question bulls have deferred, what replaces UAMPS, and on what timeline relative to the cash clock?

The Cash Hoard Was the Bull Case. UBS Just Challenged It.

For the past year, NuScale's cash position served as structural support. Bulls could argue: revenue is thin, but the company has runway to land a transformative contract. A formal Sell from a bulge-bracket bank makes that argument significantly harder to hold institutionally. With trailing EPS at -$1.86 and a forward P/E of -13.2x, there is no earnings floor to cushion further multiple compression. Investors long SMR are making a binary bet: a major commercial contract materialises before the reserve runs dry. A published 40%-downside target from UBS narrows the window institutional managers can justify holding through that uncertainty. Those who want to stress-test their own assumptions can run the numbers through the DCF calculator.

Shorts Were Positioned Before the Note Dropped

With 17.6% of the float sold short ahead of Friday's move, institutional bears were running this position well before UBS's note. The downgrade is a ratification, not a discovery. Short interest at that level signals the options market had been pricing elevated downside probability for weeks before the analyst report landed. A CFO share sale at $9.49 under a preset trading plan, disclosed before the downgrade, added to the picture of insiders and shorts aligned on the same direction before the published catalyst arrived.

A Single Contract Would Invalidate This Call

Watch for DOE licensing milestones or utility procurement announcements in Q4. A binding order implying annualised revenue meaningfully above the current $11mn TTM base is the specific event that would force short covering and reset valuation expectations. Until that news breaks, the UBS target functions as a gravitational anchor. The stock touched a 52-week low Friday. That level becomes the ceiling to beat if no commercial catalyst arrives before year-end, and with no earnings buffer to slow the descent, the post-UAMPS revenue hole leaves no cushion if selling pressure continues.

For a full read on NuScale Power's balance sheet and valuation metrics, generate a Basis Report on SMR to see the complete picture before making a position decision.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.

Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.